Search For
/
Stocks
Intraday Booster
Sector Booster
Stock Screener
Market Pulse
Screeners
More
Go Prime
My Plans
Privacy Policy
Contact
Refer & EarnScreenersMain
Stock Screener
Create Screener
Explore Screeners
Community ScreenersTrading Screeners
CandleSticks Screener
Top Gainers & Losers
Opening Range Breakout
Stock Screener AI
Stock Quality Scorecard
Overvalued StocksNewUndervalued StocksNewTechnical Screeners
NR4 Stocks
NR7 Stocks
Previous Day High Breakout
Previous Day Low Breakout
Previous Day Open Breakout
Bullish Crossover Stocks
Bearish Crossover Stocks
High Volume Shocker
VWAP Breakout Stocks
Range High Breakout
Range Low BreakoutMoreMarkets
Global Market Today
Global Indices
Indian Indices
NIfty TodaySmart Money
FII DII DataNew
FII Buying
NSE Insider Trading
SLB Stocks DataDerivatives
FnO Movements
NSE F&O Lot Size
Ban ListAnalysis & Calendars
Technical DashboardSector Booster
Sector AnalysisNew
Result Calendar
Economic Calendar
Innova Captab
Small Cap•1,600 Employees•IPO 2023
Current Price
₹678.55
-26.45 (-3.75%)Updated
Today's Range
673
₹678.55
705.55
52 Week Range
52W Low₹622.00
52W High₹1020.70
₹678.55
Downside9.09%
Upside50.42%
Price Chart
Compare with Peers
Historical Ratios
Track top 12 most important financial ratios
P/E Ratio: Price to Earnings - Most used valuation metric
Loading chart...
Analyzing Investment Quality
Processing 9 key metrics...
Key Metrics
Hover for details
Valuation
Market Cap
₹3,921.91 Cr
Market Cap
Total market value of companyP/E Ratio
29.70
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)P/B Ratio
5.23
P/B Ratio
Price to Book Value. <3 may indicate undervaluationEPS
₹22.67
EPS
Earnings Per Share. Higher and growing is positiveProfitability
ROE
6.96%
ROE
Return on Equity. >15% is good, >20% is excellentROCE
14.60%
ROCE
Return on Capital Employed. >15% is goodNet Margin
8.82%
Net Margin
Net profit as % of revenue. >10% is goodOperating Margin
-%
Operating Margin
Operating profit margin. >15% is goodGrowth
EPS Growth (5Y)
-%
EPS Growth (5Y)
5-year EPS growth. >15% is strongRevenue Growth (5Y)
-%
Revenue Growth (5Y)
5-year revenue growth. >10% is goodQtr Sales Growth
19.50%
Qtr Sales Growth
Quarter-over-quarter sales growthQtr Profit Growth
5.22%
Qtr Profit Growth
Quarter-over-quarter profit growthFinancial Health
Debt/Equity
0.35
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellentBook Value
₹167.66
Book Value
Net asset value per shareDividend Yield
-%
Dividend Yield
Annual dividend as % of price. >2% is goodPromoter Holding
50.90%
Promoter Holding
Promoter stake. >50% shows confidenceGood
Average
Needs Attention
SWOT Analysis
Strengths
4 points- •Innova Captab Ltd exhibits consistent profitability with a Return on Equity (ROE) of 14.3% and a healthy Operating Profit Margin (OPM) of 15.1%, indicating efficient operations and strong earnings generation.
- •The company shows promising growth, with quarterly sales increasing by 19.5%. This upward trend suggests a strong market demand for its products and potential for future revenue expansion.
Weaknesses
4 points- •Innova Captab Ltd has a relatively high Price-to-Earnings (P/E) ratio of 36.00, potentially indicating the stock is overvalued compared to its earnings. Investors should carefully assess the valuation.
- •The relatively low dividend yield of 0.00% might be a concern for income-seeking investors. This could limit the appeal to investors prioritizing regular dividend income from their investments.
Opportunities
3 points- •The company operates in the "Pharmaceuticals" sector, which is generally a growing industry, driven by increasing healthcare demand and innovation, offering potential for sustained revenue expansion.
- •With a relatively smaller market cap of 4673 Cr compared to peers like Sun Pharma (411665 Cr), Innova Captab has significant room for market share expansion and valuation growth within the pharma sector.
Threats
4 points- •Innova Captab faces intense competition from larger, well-established players in the Pharmaceuticals sector, such as Sun Pharma and Cipla, which could limit its market share and pricing power.
- •The pharmaceutical industry is highly regulated; changes in drug pricing policies, manufacturing standards, or approval processes could negatively impact Innova Captab's operations and profitability.
Segment-wise Financial Analysis
Fetching Financials...
Fetching Balance Sheet...
Fetching Cash Flow...
Shareholding Pattern
Loading shareholding data...
Company Insider Trading Activity
No insider trading data available
Corporate Action
Company Announcements
Technical Analysis & Indicators
Standard pivot points - most widely used
Pivot Points (CLASSIC)
| Level | Price | Distance | % Change |
|---|---|---|---|
| R4 | ₹763.50 | +₹84.95 | +12.52% |
| R3 | ₹730.95 | +₹52.40 | +7.72% |
| R2 | ₹718.25 | +₹39.70 | +5.85% |
| R1 | ₹698.40 | +₹19.85 | +2.93% |
| PIVOT | ₹685.70 | 7.15 | 1.05% |
| CURRENT | ₹678.55 | - | - |
| S1 | ₹600.75 | -₹77.80 | -11.47% |
| S2 | ₹633.30 | -₹45.25 | -6.67% |
| S3 | ₹653.15 | -₹25.40 | -3.74% |
| S4 | ₹665.85 | -₹12.70 | -1.87% |
CPR Levels
Support
Resistance
S4
N/A
S3
N/A
S2
N/A
S1
N/A
| CPR |
BC: N/AP: N/ATC: N/A
R1
N/A
R2
N/A
R3
N/A
R4
N/A
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment
is trading CPR, indicating
● CPR Width
CPR is
● Opening Range
Day's range: ~
● Price Position
Trading Inside opening range
Delivery Volume Analysis & Trading Activity
Latest Volume-6.8% vs avg
0.23L
(19 Mar 2026)Delivery %+2.6% vs avg
55.9%
(19 Mar 2026)Avg Volume (20D)20-day average
0.25L
(19 Feb - 19 Mar)Avg Delivery %Trend ↑
53.2%
(19 Feb - 19 Mar)Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.
Peer Comparison & Industry Benchmarking
Quick Compare
Largest by Market Cap
Divis Laboratories Ltd
1.64L ₹ Cr
Best Profit Growth
Sai Life Sciences Ltd
548.00 %
Highest Dividend Yield
Windlas Biotech Ltd
1.29 %
Peer Comparison
| Company Name |
|---|
 Akums Drugs & Pharmaceuticals Ltd |
 Borosil Scientific Ltd |
 Dishman Carbogen Amcis Ltd |
 Divis Laboratories Ltd |
 Indegene Ltd |
 OneSource Specialty Pharma Ltd |
 Sai Life Sciences Ltd |
 Suven Life Sciences Ltd |
 Syngene International Ltd |
 Tarsons Products Ltd |
 Vimta Labs Ltd |
 Windlas Biotech Ltd |
About
Innova Captab Ltd
Innova Captab Limited is an integrated pharmaceutical company operating in India and internationally. Its core business encompasses the entire pharmaceutical value chain, from research and development to marketing and distribution of its own products and those of other companies. This vertical integration allows for greater control over quality and efficiency throughout the process.
A significant portion of Innova Captab's business involves contract development and manufacturing organization (CDMO) services. The company provides these services to other Indian pharmaceutical firms, leveraging its manufacturing capabilities and expertise to produce drugs according to their specifications. This aspect of the business generates revenue streams independent of the company's own branded products.
Innova Captab manufactures and distributes a wide range of generic formulation products covering numerous therapeutic areas. These include but are not limited to antibiotics (cephalosporins, fluoroquinolones, macrolides), cardiovascular drugs, analgesics, anti-inflammatory agents, antidiabetic medications, and treatments for various other conditions. The company produces these drugs in diverse forms, including tablets, capsules, syrups, injections, and ointments, showcasing its versatility in pharmaceutical manufacturing.
The company's branded generic products reach the market through a multi-channel distribution strategy. This includes a traditional network of distributors and pharmacies, as well as a growing online presence via e-commerce pharmacy websites. This diversified approach allows Innova Captab to access a broader customer base and enhance market reach.
In summary, Innova Captab Limited operates a multifaceted pharmaceutical business model. It combines CDMO services for other pharmaceutical companies with the development, manufacture, and distribution of its own portfolio of branded generic drugs, achieving market access via both traditional and online channels. This integrated approach positions the company strategically within the competitive Indian and international pharmaceutical markets.
COMPANY FACTS - INNOVACAP
Registered Address
Sco-301, 2nd floor,Sector-9,
Panchkula
HARYANA
IN
Tel: 911724194500
Website:https://www.innovacaptab.com/
Investor Relations:http://www.innovacaptab.com/investor-relations.html
Company Details
Group: Pharmaceuticals, Biotechnology & Life Sciences
Sector: Health Care
Industry: Life Sciences Tools & Services
Exchange: NATIONAL STOCK EXCHANGE OF INDIA
Employees: 1,600
IPO Date: 29/12/2023
MANAGEMENT - INNOVACAP
Mr. Lokesh Bhasin
Chief Financial Officer
Ms. Neeharika Shukla
Compliance Officer, Company Secretary
Mr. Vinay Lohariwala
Managing Director
Mr. Manoj Lohariwala
Whole-Time Director
Mr. Jayant Rao
Whole-Time Director
Anup Agarwal
Director
Mr. Archit Aggarwal
Director
Mr. Gian Aggarwal
Director
Mr. Sudhir Bassi
Director
Mr. Shirish Belapure
Director
Priyanka Dixit
Director
Mahendar Korthiwada
Director
Investor Questions Answered
Innova Captab Ltd (INNOVACAP) Stock FAQs
Get answers to the most common questions about Innova Captab Ltd stock price, fundamentals, financial metrics, and investment analysis
The current share price of Innova Captab Ltd (INNOVACAP) is ₹678.55. Today, the stock has declined by ₹26.45 (3.75%), trading in a range of ₹673 to ₹705.55. The stock opened at ₹702 with a trading volume of 23,345 shares.
Innova Captab Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹3,921.91 crores, P/E ratio of 29.70, ROE of 6.96%, and ROCE of 14.60%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Innova Captab Ltd (INNOVACAP) is ₹1,020.7, while the 52-week low is ₹622. Currently trading at ₹678.55, the stock is 14.2% away from its 52-week low and 33.5% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Innova Captab Ltd stock at ₹678.55 depends on multiple factors. The stock is currently trading with a P/E ratio of 29.70 and P/B ratio of N/A. Today's performance shows a loss of 3.75%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Innova Captab Ltd offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹678.55, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Innova Captab Ltd's key financial metrics include: P/E Ratio: 29.70, P/B Ratio: N/A, ROE: 6.96%, ROCE: 14.60%, Dividend Yield: 0.00%, EPS: ₹22.67, Book Value: ₹167.66, Debt-to-Equity: 0.35, and Current Ratio: N/A. The company's market cap stands at ₹3,921.91 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Innova Captab Ltd stock opened at ₹702 and is currently trading at ₹678.55, showing a decline of ₹26.45 (3.75%). The intraday high is ₹705.55 and low is ₹673. The trading volume stands at 23,345 shares, indicating moderate market participation today.
Innova Captab Ltd has a Price-to-Earnings (P/E) ratio of 29.70, which means investors are willing to pay ₹29.70 for every ₹1 of earnings. With an EPS of ₹22.67, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
Innova Captab Ltd has a market capitalization of ₹3,921.91 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹678.55) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Innova Captab Ltd has a book value of ₹167.66 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹678.55, which is 304.7% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Innova Captab Ltd has a Return on Equity (ROE) of 6.96% and Return on Capital Employed (ROCE) of 14.60%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
Innova Captab Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Innova Captab Ltd has a debt-to-equity ratio of 0.35, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Innova Captab Ltd has an Earnings Per Share (EPS) of ₹22.67, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹678.55 and P/E ratio of 29.70, investors are paying 29.70 times the annual earnings per share. This moderate EPS suggests decent earnings generation. Track EPS growth over quarters to assess earnings momentum.
Innova Captab Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Innova Captab Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Innova Captab Ltd stock, consider: 1) Fundamental Analysis - Review P/E (29.70), ROE (6.96%), debt-to-equity (0.35), and growth rates. 2) Technical Analysis - Check 52-week range (₹622.00 - ₹1020.70), moving averages, and chart patterns. 3) Valuation - Compare current price (₹678.55) with book value (₹167.66) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Innova Captab Ltd share is ₹10.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹678.55 is 6685x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Innova Captab Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹622.00 - ₹1020.70). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.35 indicates leverage. 4) Liquidity Risk - Based on trading volume of 23,345 shares. 5) Valuation Risk - P/E of 29.70 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Innova Captab Ltd operates in the industry with key metrics: P/E ratio of 29.70, ROE of 6.96%, market cap of ₹3,921.91 crores, and dividend yield of 0.00%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.35), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Innova Captab Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹678.55, with a 52-week range of ₹622.00 to ₹1020.70. Based on fundamentals like P/E (29.70), ROE (6.96%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Innova Captab Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹678.55. 2) Fundamental Deterioration - Declining ROE (currently 6.96%), increasing debt (D/E: 0.35), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Innova Captab Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.00%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.
Menu